Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 2:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 8,317 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Standard of Care treatments Clear all
Completed Not applicable Interventional Results available

Secondary HIV Prevention and Adherence Among HIV-infected Drug Users

NCT01741311
View directory record Official record
Conditions
Risk Behavior, Medication Adherence, HIV
Interventions
3H+ (Holistic Health for HIV), HHRP+ (Holistic Health Recovery Program)
Behavioral
Lead sponsor
University of Connecticut
Other
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 8, 2025 · Synced Oct 10, 2026, 2:55 AM EDT
Withdrawn Phase 4 Interventional

Fluocinolone Acetonide Insert (ILUVIEN®) for Diabetic Macular Edema (FAD) Study

NCT02902744
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
ILUVIEN®
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 22, 2017 · Synced Oct 10, 2026, 2:55 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)

NCT05296798
View directory record Official record
Conditions
Locally Advanced or Metastatic Breast Cancer
Interventions
Phesgo, Giredestrant, Docetaxel, Paclitaxel, LHRH Agonist, Optional Endocrine Therapy of Investigator's Choice
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
922 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
10
States / cities
Tucson, Arizona • Los Angeles, California • Jacksonville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 10, 2026, 2:55 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer

NCT05379595
View directory record Official record
Conditions
Advanced or Metastatic Colorectal Cancer
Interventions
Amivantamab IV, Fluorouracil, Leucovorin, Oxaliplatin, Irinotecan, Amivantamab
Biological
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 10, 2026, 2:55 AM EDT
Not yet recruiting Not applicable Interventional

Knee Replacement Rehabilitation Care Pathways

NCT07598539
View directory record Official record
Conditions
Knee Replacement, Total
Interventions
TKA Journey - patient education, Optimized Rehab Scheduling, Usual Rehab
Behavioral · Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 10, 2026, 2:55 AM EDT
Active, not recruiting Phase 2 Interventional

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

NCT05198830
View directory record Official record
Conditions
Lung Adenocarcinoma, Lung Large Cell Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8
Interventions
Carboplatin, Cisplatin, Computed Tomography, Durvalumab, FDG-Positron Emission Tomography, Magnetic Resonance Imaging, Methoxyamine, Pemetrexed, Radiation Therapy
Drug · Procedure · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
34
States / cities
Buena Park, California • Duarte, California • Irvine, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 10, 2026, 2:55 AM EDT
Recruiting Phase 2 Interventional

MID-STEP (MIDodrine for Sepsis Treatment and Early vasoPressor Weaning) Trial

NCT06319248
View directory record Official record
Conditions
Sepsis, Low Blood Pressure
Interventions
Midodrine, Standard of Care
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
5
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Mankato, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 10, 2026, 2:55 AM EDT
Not yet recruiting Phase 4 Interventional

Epoprostenol Plus Conventional Therapy in COld and Frostbite Injury (ECCO)

NCT07424378
View directory record Official record
Conditions
Frostbite
Interventions
Standard of care plus Epoprostenol infusion for 8 hours (hrs) per day up to 5 days maximum, Standard of Care + Placebo (Normal Saline)infusion for 8 hours per day up to 5 days maximum
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 10, 2026, 2:55 AM EDT
Recruiting Phase 1 Interventional

First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies

NCT05627960
View directory record Official record
Conditions
Triple Negative Breast Cancer, Hormone-Resistant Breast Cancer, Non Small Cell Lung Cancer, Mesothelioma
Interventions
AG-01 Compound
Drug
Lead sponsor
A&G Pharmaceutical Inc.
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 28, 2022 · Synced Oct 10, 2026, 2:55 AM EDT
Completed Not applicable Interventional

Addressing Low-Income Families' Basic Social Needs at Pediatric Visits

NCT01303458
View directory record Official record
Conditions
Low Income Families Basic Social Needs
Interventions
Basic Needs Surveillance (BNS) protocol
Behavioral
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
9
States / cities
Boston, Massachusetts • Dorchester, Massachusetts • Roslindale, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2017 · Synced Oct 10, 2026, 2:55 AM EDT
Not listed Not applicable Interventional

Trial to Investigate the in Silico Optimization of Insulin Treatments

NCT03895138
View directory record Official record
Conditions
Coronary Artery Bypass
Interventions
Standard Glucommander Protocol (SGP), Optimized Glucommander (OGM)
Other
Lead sponsor
University of Virginia
Other
Eligibility
40 Years to 75 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 29, 2019 · Synced Oct 10, 2026, 2:55 AM EDT
Not yet recruiting Phase 4 Interventional

Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)

NCT07547878
View directory record Official record
Conditions
Chronic Kidney Disease, Type 2 Diabetes
Interventions
Finerenone, Semaglutide, Lotensin, Capoten, Enalapril, Monopril, Lisinopril, Univasc, Aceon, Accupril, Altace, Mavik, Edarbi, Atacand, Avapro, Cozaar, Benicar, Micardis, Diovan, Invokana, Farxiga, Jardiance, Ertugliflozin, Brenzavvy, Sotagliflozin
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 84 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Temple, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 10, 2026, 2:55 AM EDT
Not yet recruiting Phase 4 Interventional

Fibrinogen in Liver Transplant

NCT07265843
View directory record Official record
Conditions
Liver Transplant Surgery
Interventions
Intercept Fibrinogen Complex (IFC), Cryoprecipitate Antihemophilic Factor (AHF)
Biological
Lead sponsor
Trauma Hemostatis and Oxygenation Research (THOR) Network
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 5, 2025 · Synced Oct 10, 2026, 2:55 AM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer

NCT07155174
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
ABBV-706, Atezolizumab, Etoposide, Carboplatin, Lurbinectedin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
12
States / cities
New Haven, Connecticut • Gainesville, Florida • Ocala, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 10, 2026, 2:55 AM EDT
Recruiting Not applicable Interventional

Acupuncture Therapy for Pediatric Disorders of Gut-Brain Interaction

NCT07435610
View directory record Official record
Conditions
Disorders of Gut-brain Interaction
Interventions
Active Therapeutic acupuncture intervention, Sham therapeutic acupuncture treatment
Other
Lead sponsor
Children's Hospital of Orange County
Other
Eligibility
8 Years to 17 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 10, 2026, 2:55 AM EDT
Completed Phase 2 Interventional Results available

Letermovir for CMV Prevention After Lung Transplantation

NCT05041426
View directory record Official record
Conditions
Lung Transplant, CMV
Interventions
Letermovir, Valganciclovir
Drug
Lead sponsor
Fernanda P Silveira, MD, MS
Other
Eligibility
18 Years to 100 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 10, 2026, 2:55 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

PRESENCE Project: An Early Palliative Care Intervention in Brain Tumors

NCT01652768
View directory record Official record
Conditions
Malignant Brain Tumors
Interventions
Research Questionnaires, Palliative Care Team, Educational Information Session for Patients and Caregivers, Contact every 2 weeks, Follow-up Surgical Visit Session, Medical and/or Radiation Oncology Appointment Session
Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 29, 2013 · Synced Oct 10, 2026, 2:55 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Primary Connections for Youth and Families

NCT05964010
View directory record Official record
Conditions
Substance Use
Interventions
Standard Screening, Standard Psychoeducation, Standard Brief Negotiated Interview (BNI), Standard Referral to Treatment (RT), Family Screening, Family Psychoeducation, Family Brief Negotiated Interview (BNI), Family Facilitated Conversation (FC) & Referral to Treatment (RT)
Behavioral
Lead sponsor
The National Center on Addiction and Substance Abuse at Columbia University
Other
Eligibility
12 Years to 17 Years
Enrollment
2,300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 10, 2026, 2:55 AM EDT
Not yet recruiting Phase 4 Interventional

Combatting Muscle Loss in Obese Adult Patients on GLP-1 Medications Through Dietary Counseling and Exercise During Treatment Evaluates Whether a 12-week Exercise and Individualized Nutrition Program Can Reduce Muscle and Bone Loss and Improve Strength, Fitness, and Function in Obese Adults on GLP-1

NCT07554417
View directory record Official record
Conditions
GLP - 1, Obesity & Overweight, Muscle Loss, Exercise Intervention, Dietary Assessment
Interventions
Semaglutide, Dietary Counseling, Exercise
Drug · Behavioral
Lead sponsor
William Marsh Rice University
Other
Eligibility
40 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 10, 2026, 2:55 AM EDT
Completed Phase 2 Interventional Results available

Study of rADAMTS-13 (SHP655) in the Treatment of Participants With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

NCT03922308
View directory record Official record
Conditions
Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
Interventions
Placebo, SHP655, Standard of Care
Other · Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 75 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
7
States / cities
Birmingham, Alabama • Boston, Massachusetts • Minneapolis, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2022 · Synced Oct 10, 2026, 2:55 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Personalized Post-Operative Pain Management

NCT06669650
View directory record Official record
Conditions
Persistent Post Operative Opioid Use, Post-surgical Pain
Interventions
PGx guided personalized post-operative pain management, Oxycodone, Hydromorphone
Other · Drug
Lead sponsor
University of Tennessee Graduate School of Medicine
Other
Eligibility
18 Years to 85 Years
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 1, 2024 · Synced Oct 10, 2026, 2:55 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of a Very Low Calorie and Low Calorie Diet on Moderate to Severe Obstructive Sleep Apnea in Obese Adults

NCT02251574
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Low Calorie Diet, Very Low Calorie Diet, Standard Care
Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
21 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Oct 10, 2026, 2:55 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Little Lungs Study

NCT06855043
View directory record Official record
Conditions
Invasive Mechanical Ventilation, Severe Respiratory Distress Syndrome
Interventions
Calfactant, Budesonide
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
7 Days to 14 Days
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 10, 2026, 2:55 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Parent Emotion Coaching for Anorexia Nervosa

NCT04421989
View directory record Official record
Conditions
Anorexia Nervosa, Atypical Anorexia Nervosa
Interventions
Emotion Coaching, Support Group
Behavioral · Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
12 Years to 17 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 26, 2025 · Synced Oct 10, 2026, 2:55 AM EDT